Tveit, Sjur H.
Myhre, Peder L.
Hanssen, Tove Aminda
Forsdahl, Signe Helene
Iqbal, Amjid
Omland, Torbjørn
Schirmer, Henrik
Funding for this research was provided by:
Norges Forskningsråd
Article History
Received: 30 August 2021
Accepted: 17 December 2021
First Online: 18 January 2022
Competing interests
: TO is a member of the IFCC Committee om Cardiovascular Biomarkers and has received non-financial institutional support from Novartis, Abbott Diagnostics, Roche Diagnostics and SomaLogic, as well as consulting fees and lecture honoraria from Roche Diagnostics, Abbott Diagnostics, CardiNor and Siemens Healthineers. He holds several non-related patents in the field of biomarkers, as well as stock options in CardiNor. PLM has participated in advisory boards for AstraZeneca, Novartis and Novo Nordisk and received lecture honoraria from AmGen, AstraZeneca, Boehringer-Ingelheim, Novartis and Novo Nordisk. HS has received research grants from AstraZeneca, as well as consulting fees and lecture honoraria from AstraZeneca, MSD, Sanofi and Pfizer. The other authors report no conflicts of interest pertaining to this article.